Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has shared an update.
Pharmaron Beijing Co., Ltd. announced a supplemental update regarding its acquisition of an 82.54% interest in Biortus, a move that constitutes a connected transaction. The company conducted a comprehensive valuation of Biortus by comparing it with four other listed companies in the same industry, focusing on profitability as a key indicator. This acquisition is expected to strengthen Pharmaron’s position in the CRO market, leveraging Biortus’ steady growth in revenue and profits.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a joint stock company based in China, primarily engaged in providing comprehensive drug research, development, and manufacturing services throughout the research and development cycle. Over 50% of its revenue is generated from Contract Research Organization (CRO) businesses.
YTD Price Performance: 67.45%
Average Trading Volume: 10,219,281
Technical Sentiment Signal: Buy
Current Market Cap: HK$57.23B
For a thorough assessment of 3759 stock, go to TipRanks’ Stock Analysis page.